Lawsuit Filed Against PROCEPT BioRobotics Over Alleged Securities Fraud Claims

Legal Action Against PROCEPT BioRobotics

Hagens Berman Sobol Shapiro LLP has announced that it is pursuing a securities class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) following serious claims concerning the company’s sales practices and communication with investors. The lawsuit reveals a troubling pattern of conduct that allegedly misled shareholders regarding the company’s financial health, particularly in relation to the sales of its single-use handpiece, a vital component of its Aquablation therapy used in treating enlarged prostates.

Background of the Lawsuit

The class action aims to represent investors who made purchases or secured PROCEPT’s common stock between February 28, 2024, and February 25, 2026. Within this timeframe, the lawsuit alleges that PROCEPT knowingly misrepresented critical sales information and operational data, specifically around the handpiece sales in the United States. This miscommunication potentially inflated reported unit sales and revenues.

Fundamentally, the charges outline that during this period, PROCEPT adopted an aggressive discount strategy to stimulate bulk orders from its customers, which inadvertently led to inflated sales figures, overshadowing the reality of their stock and inventory situation. Investors claim that they were unaware that such sales practices had a manipulative intent, pulling sales forward at the cost of future performance outcomes.

Major Events Leading to the Lawsuit

The case highlights significant announcements from PROCEPT that contributed to the growing controversy and eventual lawsuit. First, on August 6, 2025, the company disclosed disappointing Q2 2025 financial results that showcased a dramatic drop in handpiece sales. This announcement caught investors off guard as it significantly missed market expectations.

Later, during the November 4, 2025, earnings report, further disappointments emerged. PROCEPT’s management was forced to reduce its annual sales guidance, revealing its struggles with managing customer inventory levels adequately. Remarkably, some clients were reportedly holding excessive inventory, leading to more confusion regarding the stability of PROCEPT's sales performance.

In a striking turn, on February 25, 2026, the company released its Q4 2025 results showing a shocking excess of over 10,000 handpiece units held in customer inventories. PROCEPT’s announcement revealed that U.S. handpiece sales had plummeted by 30% sequentially, a drastic fall that confirmed investor fears of artificial inflation in sales numbers.

Investigative Focus and Implications

Reed Kathrein, the leading attorney at Hagens Berman handling the case, stated, “We’re focused on whether PROCEPT may have intentionally pulled in sales from future quarters to create a façade of meeting market expectations, and if they had been sufficiently transparent during communications with their investors.” This statement underlines the severity of the allegations, which have substantial implications for corporate governance and investor protection.

As a result of the unfolding situation, PROCEPT’s stock experienced a drastic decline, suffering a loss of over 48% from the value recorded on August 6, 2025, when the company first misled investors with optimistic sales forecasts.

Impact on Investors

This unfolding scenario raises concerns for investors who have suffered significant losses due to potentially deceptive practices. Hagens Berman is calling on anyone affected by these events to step forward and share their experiences. They urge those with relevant knowledge or who wish to seek further information about their rights as investors to reach out to their legal team.

The firm also points out that stakeholders with non-public information regarding PROCEPT may consider leveraging the SEC Whistleblower program, which encourages individuals to provide original information related to securities violations.

In striving for accountability, the lawsuit also emphasizes Hagens Berman's commitment to representing various entities impacted by corporate wrongdoing. The firm has previously secured extensive settlements in cases involving similar allegations, underscoring their focus on fostering corporate responsibility and transparency.

For investors or individuals needing additional support, resources are available on the firm’s website, which contains further details about the class action, the timeline for participation, and how affected investors can document their losses.

This developing case against PROCEPT BioRobotics spotlights significant issues pertaining to corporate transparency and the integrity of investor communications. As the story evolves, it remains essential for stakeholders to stay informed and engaged with the proceedings to safeguard their interests in a dynamic financial landscape.